1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY

Abstract Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in pts who have already been selected for ST. Prospectively we examined the EFS as a predictor of adverse outcomes in older pts undergoing ST. Methods: Candidates seen by a Medical Oncologist and deemed appropriate for ST ≥65years, starting new ST were included. EFS, demographics, diagnosis, ECOG performance status (PS) and adverse events using the NCI CTCAE v4.03 were assessed. The association between EFS and toxicity was examined during one treatment cycle using Pearson's correlation coefficient (r). Results: From Feb-April 2014, 24 pts were included (table), median age 72 years (65–92). EFS results were; No frailty 10 (42%), Apparently vulnerable 8 (33%), Mild frailty 4 (17%), Moderate frailty 1 (4%) and Severe frailty 1 (4%). Many were of good PS (54% had ECOG 1). All toxicities were recorded with most common non-lab toxicities being fatigue 12 (50%) and pain 8 (33%), all ≤grade III. The most common lab toxicities were Hb and Alk Phos. During ST there were 3 (13%) admissions, 6 (25%) had treatments held or dose adjustments and 1 death occurred. Age and ECOG were significantly correlated (r=0.43, p =